Gavin Giovannoni

42.6k total citations · 11 hit papers
678 papers, 26.2k citations indexed

About

Gavin Giovannoni is a scholar working on Pathology and Forensic Medicine, Neurology and Oncology. According to data from OpenAlex, Gavin Giovannoni has authored 678 papers receiving a total of 26.2k indexed citations (citations by other indexed papers that have themselves been cited), including 394 papers in Pathology and Forensic Medicine, 162 papers in Neurology and 120 papers in Oncology. Recurrent topics in Gavin Giovannoni's work include Multiple Sclerosis Research Studies (372 papers), Polyomavirus and related diseases (85 papers) and Peripheral Neuropathies and Disorders (83 papers). Gavin Giovannoni is often cited by papers focused on Multiple Sclerosis Research Studies (372 papers), Polyomavirus and related diseases (85 papers) and Peripheral Neuropathies and Disorders (83 papers). Gavin Giovannoni collaborates with scholars based in United Kingdom, United States and Germany. Gavin Giovannoni's co-authors include Ruth Dobson, David Baker, Sreeram V Ramagopalan, Klaus Schmierer, Gareth Pryce, Giulio Disanto, George C. Ebers, Adam E. Handel, Axel Petzold and Per Soelberg Sørensen and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and SHILAP Revista de lepidopterología.

In The Last Decade

Gavin Giovannoni

653 papers receiving 25.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multiple sclerosis – a review

2018 1.4k citations Ruth Dobson, Gavin Giovannoni European Journal of Neurology profile →
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

2010 689 citations Gavin Giovannoni, Gıancarlo Comı et al. New England Journal of Medicine profile →
A ChIP-seq defined genome-wide map of vitamin D receptor binding: Associations with disease and evolution

2010 665 citations Giulio Disanto, Julia M. Morahan et al. profile →
The peripheral benzodiazepine binding site in the brain in multiple sclerosis

2000 546 citations Gavin Giovannoni et al. profile →
Meta‐analysis of early nonmotor features and risk factors for Parkinson disease

2012 515 citations Alastair J. Noyce, Jonathan P. Bestwick et al. profile →
Neurofilament light chain

2015 390 citations Ching‐Hua Lu, Corrie Macdonald‐Wallis et al. Neurology profile →
Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

2013 366 citations Niklas Norgren, Ruth Dobson et al. profile →
Brain health: time matters in multiple sclerosis

2016 306 citations Gavin Giovannoni, Maria Pia Sormani et al. Multiple Sclerosis and Related Disorders profile →
Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

2015 275 citations Gavin Giovannoni, Sharmilee Gnanapavan et al. Multiple Sclerosis and Related Disorders profile →
Smouldering multiple sclerosis: the ‘real MS’

2022 148 citations Gavin Giovannoni et al. Therapeutic Advances in Neurological Disorders profile →
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis

2025 26 citations Robert J. Fox, Amit Bar-Or et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gavin Giovannoni United Kingdom	79	14.1k	7.2k	4.4k	4.3k	4.2k	678	26.2k
Michael Hutchinson Ireland	54	13.9k 1.0×	6.6k 0.9×	3.6k 0.8×	2.5k 0.6×	3.4k 0.8×	295	21.8k
Jeffrey A. Cohen United States	69	13.2k 0.9×	5.6k 0.8×	3.1k 0.7×	4.1k 0.9×	2.6k 0.6×	314	22.7k
Ralf Gold Germany	78	10.4k 0.7×	8.1k 1.1×	4.5k 1.0×	6.3k 1.5×	7.1k 1.7×	780	28.2k
Gıancarlo Comı Italy	95	17.6k 1.2×	10.2k 1.4×	3.4k 0.8×	6.3k 1.5×	3.5k 0.8×	762	36.2k
Richard A. Rudick United States	71	16.0k 1.1×	5.5k 0.8×	3.4k 0.8×	3.2k 0.7×	2.9k 0.7×	214	21.7k
Amit Bar‐Or Canada	83	14.5k 1.0×	5.8k 0.8×	4.0k 0.9×	5.0k 1.2×	9.1k 2.2×	453	25.9k
Paul O’Connor Canada	52	19.7k 1.4×	6.9k 1.0×	5.1k 1.1×	3.4k 0.8×	4.3k 1.0×	152	25.1k
Tomas Olsson Sweden	92	14.4k 1.0×	5.5k 0.8×	4.9k 1.1×	5.8k 1.3×	10.6k 2.5×	679	31.2k
Moses Rodriguez United States	79	13.7k 1.0×	6.1k 0.9×	2.9k 0.6×	5.4k 1.3×	6.5k 1.5×	489	27.0k
Eva Havrdová Czechia	57	18.7k 1.3×	6.2k 0.9×	5.2k 1.2×	3.1k 0.7×	4.4k 1.0×	385	23.5k

Countries citing papers authored by Gavin Giovannoni

Since Specialization

Citations

This map shows the geographic impact of Gavin Giovannoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gavin Giovannoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gavin Giovannoni more than expected).

Fields of papers citing papers by Gavin Giovannoni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gavin Giovannoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gavin Giovannoni. The network helps show where Gavin Giovannoni may publish in the future.

Co-authorship network of co-authors of Gavin Giovannoni

This figure shows the co-authorship network connecting the top 25 collaborators of Gavin Giovannoni. A scholar is included among the top collaborators of Gavin Giovannoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gavin Giovannoni. Gavin Giovannoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fox, Robert J., Amit Bar-Or, Anthony Traboulsee, et al.. (2025). Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis. New England Journal of Medicine. 392(19). 1883–1892. 26 indexed citations breakdown →

Giovannoni, Gavin, Thomas Leist, Dominic Jack, et al.. (2023). Post-Approval Safety of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: 2023 Update. Multiple Sclerosis and Related Disorders. 80. 105309–105309.

Stefano, Nicola De, Maria Pia Sormani, Gavin Giovannoni, et al.. (2021). Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies. Multiple Sclerosis Journal. 28(1). 111–120. 21 indexed citations

Rieckmann, Peter, Diego Centonze, Gavin Giovannoni, et al.. (2021). Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice. Therapeutic Advances in Neurological Disorders. 14. 4203339386–4203339386. 11 indexed citations

Giovannoni, Gavin, Gıancarlo Comı, Kottil Rammohan, et al.. (2021). Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies. Advances in Therapy. 38(9). 4975–4985. 23 indexed citations

Giovannoni, Gavin, et al.. (2021). Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study. Multiple Sclerosis Journal. 28(8). 1219–1228. 23 indexed citations

Jacobs, Benjamin M., Jonathan P. Bestwick, Cornelis Blauwendraat, et al.. (2020). Parkinson’s disease determinants, prediction and gene–environment interactions in the UK Biobank. Journal of Neurology Neurosurgery & Psychiatry. 91(10). 1046–1054. 74 indexed citations

Jacobs, Benjamin M., et al.. (2020). Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom. BMC Public Health. 20(1). 912–912. 106 indexed citations

Dobson, Ruth & Gavin Giovannoni. (2018). Multiple sclerosis – a review. European Journal of Neurology. 26(1). 27–40. 1360 indexed citations breakdown →

10.

Holden, David W., Julian Gold, Christopher H. Hawkes, et al.. (2018). Epstein Barr virus shedding in multiple sclerosis: Similar frequencies of EBV in saliva across separate patient cohorts. Multiple Sclerosis and Related Disorders. 25. 197–199. 13 indexed citations

11.

Álvarez-González, César, Joela Mathews, Sharmilee Gnanapavan, et al.. (2017). Treating multiple sclerosis with generic cladribine. Queen Mary Research Online (Queen Mary University of London). 1 indexed citations

12.

Giovannoni, Gavin, Per Soelberg Sørensen, Stuart D. Cook, et al.. (2017). Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Multiple Sclerosis Journal. 24(12). 1594–1604. 243 indexed citations

13.

Stefano, Nicola De, Antonio Giorgio, Marco Battaglini, et al.. (2017). Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Multiple Sclerosis Journal. 24(2). 222–226. 48 indexed citations

14.

Pakpoor, Jina, et al.. (2016). Risks of psychiatric disorders in children and young adults with demyelinating diseases of the central nervous system: a national record-linkage study.. Multiple Sclerosis Journal. 22. 17–17. 4 indexed citations

15.

Pakpoor, Julia, Clare J. Wotton, Klaus Schmierer, Gavin Giovannoni, & Michael J Goldacre. (2016). Gender identity disorders and multiple sclerosis risk: A national record-linkage study. Multiple Sclerosis Journal. 22(13). 1759–1762. 35 indexed citations

16.

Lu, Ching‐Hua, Corrie Macdonald‐Wallis, Elizabeth Gray, et al.. (2015). Neurofilament light chain. Neurology. 84(22). 2247–2257. 390 indexed citations breakdown →

17.

Disanto, Giulio, George Chaplin, Julia M. Morahan, et al.. (2012). Month of birth, vitamin D and risk of immune-mediated disease: a case control study. BMC Medicine. 10(1). 69–69. 109 indexed citations

18.

Ramagopalan, S V, Jenny Link, Jake Byrnes, et al.. (2009). HLA-DRB1 and month of birth in multiple sclerosis. Neurology. 73(24). 2107–2111. 38 indexed citations

19.

Farrell, Rachel & Gavin Giovannoni. (2007). Development and validation of luciferase reporter gene assay to measure anti-interferon beta neutralizing antibodies. UCL Discovery (University College London). 1 indexed citations

20.

Pryce, Gareth, Gavin Giovannoni, & David Baker. (2003). Mifepristone or inhibition of 11β-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Δ(9)-tetrahydrocannabinol in mice. Neuroscience Letters. 341(2). 164–166. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact